SCHEMBL30980642

SCHEMBL30980642

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCOCCOCCNC(=O)NCCOCCOCCOCCOCCOCCN

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ MDK P21741 1/20 0.37
▸ LGALS8 O00214 1/20 0.36
▸ LGALS3 P17931 1/20 0.36
▸ LGALS4 P56470 1/20 0.36
▸ CD69 Q07108 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980606 0.96 MAPK1 (0.47) MAPK1ALDH1A1THRBMDKLGALS8
SCHEMBL30980481 0.93 MAPK1 (0.49) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL30980681 0.93 MAPK1 (0.49) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL30980568 0.91 MAPK1 (0.38) MAPK1ALDH1A1THRBMDKLGALS8
SCHEMBL30980649 0.89 MAPK1 (0.43) MAPK1ALDH1A1THRBMDKLGALS8
SCHEMBL30980709 0.88 MAPK1 (0.41) MAPK1ALDH1A1THRBMDKLGALS8
SCHEMBL30980511 0.88 MAPK1 (0.53) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL31384251 0.88 MAPK1 (0.53) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL31384238 0.88 MAPK1 (0.53) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL30980757 0.85 MAPK1 (0.46) MAPK1ALDH1A1THRBMDKLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback